Fig. 5

PIK3R3 is crucial for ovarian cancer spheroid-forming ability in vitro. A Reduction in the spheroid size of A2780-SP cells following siRNA-mediated PIK3R3 knockdown. On 3 and 5 days after siRNA transfection on A2780-SP cells, the photo was taken under EVOS 7500. B The mRNA expression of OCT4 from PIK3R3 siRNA treated A2780-SP cells. The lysate after 3 days after transfection with PIK3R3 siRNA was used for RT-qPCR to see the mRNA level of PIK3R3 and OCT4. Data are presented as the mean ± SD from three independent experiments. * **P < 0.01; ***P < 0.001. C Reduction in the spheroid size of A2780-SP and SKOV3-SP cells after PF-04691502 treatment. On 7 days from DMSO or PF-04691502 treated A2780-SP and SKOV3-SP, the morphology of sphere formation was taken under EVOS7500. Right panel showed the quantification of the sphere size (n ≥ 5). Data are presented as the mean ± SD from three independent experiments. **P < 0.01; ***P < 0.001. Scale bar = 200 nm. D The mRNA expression of OCT4 from A2780-SP and SKOV3-SP cells after PF-04691502 treatment. On 7 days from DMSO or PF-04691502 treated A2780-SP and SKOV3-SP, total lysate was used for RT-qPCR to see the mRNA level of OCT4. Data are presented as the mean ± SD from three independent experiments. ***P < 0.001. E The mRNA expression of PIK3R3 from OCT4 shRNA treated A2780 cells. The lysate after 3 days after transfection with OCT4 shRNA was used for RT-qPCR to see the mRNA level of PIK3R3 and OCT4. Data are presented as the mean ± SD from three independent experiments. **P < 0.01; ***P < 0.001